中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

预测原发性肝癌肝移植术后复发转移的分子标志物研究进展

陈曼 张霞

引用本文:
Citation:

预测原发性肝癌肝移植术后复发转移的分子标志物研究进展

DOI: 10.3969/j.issn.1001-5256.2014.12.032
基金项目: 

国家自然科学基金资助项目(30400524); 南京军区福州总医院创新团队建设专项资助; 

详细信息
  • 中图分类号: R735.7

Research advances in molecular prediction of recurrence and metastasis of primary liver cancer after liver transplantation

Research funding: 

 

  • 摘要: 肝移植是根治原发性肝癌的一个重要的治疗方法,但是术后高复发转移率却严重影响了其治疗肝癌的疗效。随着分子生物学的深入研究,发现了许多与肝癌肝移植术后复发转移相关的指标。主要从基因水平、蛋白质表达、肿瘤标志物、血清病毒等方面对这些指标进行归纳总结,并分析其对肝移植术后肿瘤复发转移的预测价值。认为尽管越来越多的分子标志物被发现,但仍不足以指导临床。因此,仍需继续加强研究,以便寻找合适的分子标志物来预测肿瘤的复发及转移。

     

  • [1]CESCON M, RAVAIOLI M, GRAZI GL, et al.Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma[J].J Transplant, 2010, 2010.
    [2]YUAN RH, JENG YM, HU RH, et al.Role of p53 and betacatenin mutations in conjunction with CK19 expression on early tumor recurrence and prognosis of hepatocellular carcinoma[J].J Gastrointest Surg, 2011, 15 (2) :321-329.
    [3]LIU J, MA Q, ZHANG M, et al.Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma:evidence from a systematic review and meta-analysis[J].Eur J Cancer, 2012, 48 (15) :2328-2338.
    [4]GUZMAN G, ALAGIOZIAN-ANGELOVA V, LAYDEN-ALMER JE, et al.P53, Ki-67, and serum alpha feto-protein as predictors of hepatocellular carcinoma recurrence in liver transplant patients[J].Mod Pathol, 2005, 18 (11) :1498-1503.
    [5]GUO XD, LI HW, ZHANG M, et al.Value of expression of MMP-2, MMP-9 and P53 in forecast of tumor recurrence and metastasis after liver transplantation[J].Prog Mod Biomed, 2011, 11 (1) :90-93. (in Chinese) 郭晓东, 李捍卫, 张敏, 等.MMP-2、MMP-9及P53的表达在肝移植后肿瘤复发与转移预测中的价值研究[J].现代生物医学进展, 2011, 11 (1) :90-93.
    [6]RANCHAL I, GONZALEZ R, BELLO RI, et al.The reduction of cell death and proliferation by p27 (Kip1) minimizes DNA damage in an experimental model of genotoxicity[J].Int J Cancer, 2009, 125 (10) :2270-2280.
    [7]CHEN ZL, WANG XH, ZHANG F, et al.Significance of expressions of P27, P53 and FAK in recurrence and metastasis of liver cancer for patients after liver transplantation[J].Med J The Chin People's Armed Police Forces, 2005, 16 (3) :184-187. (in Chinese) 陈兆雷, 王学浩, 张峰, 等.P27、P53及FAK的表达与肝癌肝移植后肿瘤复发与转移关系的研究[J].武警医学, 2005, 16 (3) :184-187.
    [8]MARSH JW, FINKELSTEIN SD, DEMETRIS AJ, et al.Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival[J].Liver Transpl, 2003, 9 (7) :664-671.
    [9]LEE JM, YANG J, NEWELL P, et al.Beta-Catenin signaling in hepatocellular cancer:Implications in inflammation, fibrosis, and proliferation[J].Cancer Lett, 2014, 343 (1) :90-97.
    [10]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.
    [11] ZULEHNER G, MIKULA M, SCHNELLER D, et al.Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence[J].Am J Pathol, 2010, 176 (1) :472-481.
    [12]FIORENTINO M, ALTIMARI A, RAVAIOLI M, et al.Predictive value of biological markers for hepatocellular carcinoma patients treated with orthotopic liver transplantation[J].Clin Cancer Res, 2004, 10 (5) :1789-1795.
    [13]NAGOSHI S.Osteopontin:versatile modulator of liver diseases[J].Hepatol Res, 2014, 44 (1) :22-30.
    [14]DENG B, ZHANG XF, ZHU XC, et al.Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection[J].Oncol Rep, 2013, 30 (6) :2795-2803.
    [15]CHENG J, WANG W, SUN C, et al.Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma[J].J Clin Gastroenterol, 2014, 48 (9) :806-814.
    [16]SIEGHART W, WANG X, SCHMID K, et al.Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria[J].J Hepatol, 2011, 54 (1) :89-97.
    [17]YAO DF, QIU LW, WU W, et al.Dynamic alterations of VEGF and intervention of its expression on effect of hepatocyte malignant transformation[J].Natl Med J China, 2010, 90 (42) :3014-3018. (in Chinese) 姚登福, 邱历伟, 吴玮, 等.血管内皮生长因子动态表达及干预对肝细胞癌变的影响[J].中华医学杂志, 2010, 90 (42) :3014-3018.
    [18]JIA ZZ, JIANG GM, FENG YL.Serum HIF-1alpha and VEGF levels pre-and post-TACE in patients with primary liver cancer[J].Chin Med Sci J, 2011, 26 (3) :158-162.
    [19]DENG ZG, LI B, ZU C.The effect of allogenic hematopoietic stem cell transplantation on tumor recurrence and metastasis of hepatocellular carcinoma after hepatectomy and the relationship with presence of AFP mRNA and VEGF-C mRNA in peripheral blood[J].J Sichuan Univ:Med Sci Edi, 2010, 41 (2) :256-260. (in Chinese) 邓志刚, 李波, 祖存.造血干细胞移植对肝癌术后复发转移的影响及其与外周血AFP mRNA和VEGF-C mRNA关系的初步研究[J].四川大学医学报:医学版, 2010, 41 (2) :256-260.
    [20]YANG ZL, ZOU WW.Prevention of tumor recurrence with Sorafenib after liver transplantation in rat with liver cancer[J/CD].Chin J Clinicians:Electronic Edition, 2011, 5 (2) :335-342. (in Chinese) 杨振林, 邹伟伟.索拉非尼防治大鼠肝癌肝移植术后肿瘤转移复发的研究[J/CD].中华临床医师杂志:电子版, 2011, 5 (2) :335-342.
    [21]MAN K, LO CM, XIAO JW, et al.The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation[J].Ann Surg, 2008, 247 (6) :1049-1057.
    [22]ZENG JX, XIA HM, ZHU DL, et al.Expression and clinical significance of MMP-2 and VEGF in recipients of hepatocellular carcinoma accepted liver transplantation[J].J Sun Yat-Sen Univ:Medical Sciences, 2013, 34 (2) :262-265. (in Chinese) 曾纪晓, 夏慧敏, 朱德力, 等.基质金属蛋白酶-2和血管内皮生长因子在肝癌肝移植受体的表达和意义[J].中山大学学报:医学科学版, 2013, 34 (2) :262-265.
    [23]YAN WW, HUANG A, LI YG, et al.Expressions of CD34 and CD117in human hepatocellular carcinomas and the clinical significance[J].Chin J Hepatol, 2011, 19 (8) :588-593. (in Chinese) 闫伟伟, 黄昂, 李永纲, 等.CD34与CD117在人肝癌组织中的表达及其临床意义[J].中华肝脏病杂志, 2011, 19 (8) :588-593.
    [24]WANG Y, ZHANG XH, GUO P, et al.Tumor microvascular density detected by anti-CD105 and anti-CD34 in hepatocellular carcinoma patients and its predictive value of tumor recurrence after liver transplantation[J].J Sichuan Univ:Med Sci Edi, 2010, 41 (5) :818-821. (in Chinese) 王瑜, 张秀辉, 郭鹏, 等.MVD-CD105和MVD-CD34在肝细胞肝癌中的表达及其与肝移植预后的关系[J].四川大学学报:医学版, 2010, 41 (5) :818-821.
    [25]PADRISSA-ALTES S, ZAOUALI MA, FRANCO-GOU R, et al.Matrix metalloproteinase 2 in reduced-size liver transplantation:beyond the matrix[J].Am J Transplant, 2010, 10 (5) :1167-1177.
    [26]WANG J, CHEN L, LI Y, et al.Overexpression of cathepsin Z contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma[J].PLo S One, 2011, 6 (9) :e24967.
    [27]WU LM, ZHANG F, XIE HY, et al.MMP2 promoter polymorphism (C-1306T) and risk of recurrence in patients with hepatocellular carcinoma after transplantation[J].Clin Genet, 2008, 73 (3) :273-278.
    [28]ZHANG C, BAI DS, HUANG XY, et al.Prognostic significance of Capn4 overexpression in intrahepatic cholangiocarcinoma[J].PLo S One, 2013, 8 (1) :e54619.
    [29]BAI DS, DAI Z, ZHOU J, et al.Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma[J].Hepatology, 2009, 49 (2) :460-470.
    [30]YAPRAK O, AKYILDIZ M, DAYANGAC M, et al.AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma[J].Hepatobiliary Pancreat Dis Int, 2012, 11 (3) :256-261.
    [31]FAWZY MONTASER M, AMIN SAKR M, OMAR KHALIFA M.Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma[J].Arab J Gastroenterol, 2012, 13 (1) :9-13.
    [32]LI YF, ZHOU DH.Prediction value of alpha-fetoprotein andα-L-fucosidase during the hepatoma recurrence post-transplantation of liver[J].Chin J Curr Adv Gen Surg, 2009, 12 (10) :866-868. (in Chinese) 李耀锋, 周丁华.AFP和AFU预测原发性肝癌肝移植术后复发的价值[J].中国现代普通外科进展, 2009, 12 (10) :866-868.
    [33]WANG K, GUO W, LI N, et al.Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy:a large-scale, long-term study[J].Br J Cancer, 2014, 110 (7) :1811-1819.
    [34]WAN P, ZHANG J, LONG X, et al.Serum levels of preoperative alpha-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation[J].Eur J Gastroenterol Hepatol, 2014, 26 (5) :553-561.
    [35]LUO HQ, WANG ZG, LI L, et al.Study on the correlation between serum markers of hepatitis B and HBV-DNA[J].Int J Virol, 2013, 20 (6) :265-269. (in Chinese) 罗慧琴, 王志刚, 李玲, 等.乙型肝炎血清标志物和HBVDNA载量相关性分析[J].国际病毒学杂志, 2013, 20 (6) :265-269.
    [36]DU Y, SUT, DING Y, et al.Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation[J].Hepat Mon, 2012, 12 (10) :e6031.
    [37]CAMPSEN J, ZIMMERMAN M, TROTTER J, et al.Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues[J].Liver Transpl, 2013, 19 (9) :1020-1029.
    [38]KRAWCZYK M, GRATM, KORNASIEWICZ O, et al.Results of liver transplantation in the Department of General, Transplant and Liver Surgery at the Medical University of Warsaw in patients with chronic hepatitis B and C viruses infection[J].Przegl Epidemiol, 2013, 67 (1) :5-10, 93-17.
  • 加载中
计量
  • 文章访问数:  2542
  • HTML全文浏览量:  20
  • PDF下载量:  539
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-05-13
  • 出版日期:  2014-12-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回